ERBB2 and neoplasm: Key histopathological data for this group of patients are presented in Table 1 and 80% had MBD type C or D; almost equal numbers of patients had breast cancer subtypes HER2+ (35%), triple negative (31%), or luminal (34%); 96% had histological Grade 2 or 3; 83% had a T (tumor) size of 1–2; 97% had a nodal status of N0 (50%) or N1 (47%); and 52% of patients had an Ob-R positivity of >50% (+2, +3) vs. 48% of patients with an Ob-R positivity of ≤50% (0, +1) (Figure 1).